Deuterx

DeuteRx: Revolutionizing the Pharmaceutical Industry with Deuterium-Enabled Chiral Switching

DeuteRx is a virtual biopharmaceutical company that was established in 2012 with a mission to improve racemic drugs for patients. The company's team of experts has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. This revolutionary strategy stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures, reducing deleterious side-effects and improving efficacy.

The pharmaceutical industry has long been plagued by the issue of racemic mixtures, which are composed of two mirror-image molecules known as enantiomers. While these enantiomers may appear identical, they can have vastly different biological effects on the human body. In many cases, one enantiomer may be responsible for therapeutic benefits while the other can cause harmful side-effects.

DeuteRx's DECS technology addresses this problem by selectively replacing hydrogen atoms with deuterium atoms in one enantiomer, creating an isotopically labeled compound that can be separated from its counterpart using standard chromatography techniques. This process results in a pure single-enantiomer drug product that is more effective and safer than its racemic predecessor.

The company has applied DECS to a wide range of clinical therapies, including cardiovascular disease, cancer treatment, and pain management. One notable success story is their work on dextromethorphan (DM), an over-the-counter cough suppressant commonly found in cold medicines. DM is sold as a racemic mixture containing both dextro- and levo-enantiomers; however, only the dextro-enantiomer provides cough suppression while the levo-enantiomer can cause hallucinations at high doses.

Using DECS technology, DeuteRx was able to isolate pure dextromethorphan, resulting in a more effective and safer cough suppressant. The company has also applied DECS to other drugs such as ketamine, which is used for anesthesia and pain management, and tamoxifen, which is used to treat breast cancer.

DeuteRx's innovative approach has garnered attention from the pharmaceutical industry and investors alike. In 2019, the company raised $50 million in a Series C funding round led by RA Capital Management. This funding will be used to advance their pipeline of DECS-enabled drugs through clinical trials.

In conclusion, DeuteRx is revolutionizing the pharmaceutical industry with its groundbreaking DECS technology. By isolating pure single-enantiomer drug products from racemic mixtures, DeuteRx is improving patient outcomes while reducing harmful side-effects. With a strong pipeline of DECS-enabled drugs and significant investment backing, DeuteRx is poised for continued success in the years ahead.